Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Omnicare net sales up in Q1
The company posted a gross profit of $337.91m for the first quarter of 2011, compared to $343.46m for the same period in 2010. For the first quarter of
The company posted a gross profit of $337.91m for the first quarter of 2011, compared to $343.46m for the same period in 2010. For the first quarter of
Research and development expenses were $3.3m, compared to $1.1m for the same period in 2010, primarily related to the advancement of the Phase III clinical development program for
For the third quarter ended 31 March 2011, the company’s loss from operations was $15.1m, as compared to $12.22m for the same period last year. ImmunoGen has posted
The trial aims to characterize the safety profile of NTx-428 when administered to patients who have sustained a TBI. The company expects to complete the recruitment of 10
Patients eligible for this comparative study are previously treated with an anthracycline and a taxane during first-line therapy for metastatic disease. Phase 2 trial underlines Phase 1 eniluracil/5-FU/leucovorin
Vyvanse, a prescription medicine used for the treatment of Attention-Deficit/Hyperactivity Disorder (ADHD), is administered orally as adjunctive therapy. Vyvanse was administered to 92 clinically stable patients with predominant
VEGF Trap-Eye, a human fusion protein and a highly potent blocker of the growth factors, is believed to decrease vascular permeability and edema and prevent the inappropriate growth
This is the 10th US patent issued to Dyadic adding to its portfolio of 74 international patents. The inventions exhibited by this patent relate to the use of
Biovista is a biotechnology company that profiles novel uses and side effects for existing drugs using their mechanism of action. Biovista president Aris Persidis said they look forward
Net profit increased by 23% to DKK4,073m. Gross margin improved by 0.3% in local currencies, reflecting a favorable product mix development, but due to a negative currency effect,